Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05919329 · ClinicalTrials.gov registry record · Phase 4
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
A Phase 4 study of Prostate Adenocarcinoma and Castration-resistant Prostate Cancer, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05919329: Recruiting Phase 4 study of Prostate Adenocarcinoma and Castration-resistant Prostate Cancer, sponsored by OHSU Knight Cancer Institute.
NCT05919329 is a Phase 4 study of Prostate Adenocarcinoma and Castration-resistant Prostate Cancer that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 80 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05919329, a Phase 4 study of Prostate Adenocarcinoma and Castration-resistant Prostate Cancer, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.
Primary Outcome
Evaluate the change in SUVmax between baseline and Day 8 using a paired t-test to determine how hormonal therapy affects the PSMA modulation.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
- DRUG Piflufolastat
- PROCEDURE PSMA PET/CT Scan
- PROCEDURE PSMA PET/MRI scan
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2030-09-01 |
| Phase | Phase 4 |
What NCT05919329 shows while recruiting
NCT05919329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (63% lower).
The record links to 3 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05919329 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05919329 about?
NCT05919329 is a clinical study titled "Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy". This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging a...
What is the current status of trial NCT05919329?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2024-06-25. Estimated completion is 2030-09-01.
What conditions does trial NCT05919329 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Castration-resistant Prostate Cancer, Castration Sensitive Prostate Cancer.
What interventions are being tested in trial NCT05919329?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER), Piflufolastat (DRUG), PSMA PET/CT Scan (PROCEDURE), PSMA PET/MRI scan (PROCEDURE).
Who is sponsoring clinical trial NCT05919329?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05919329 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05919329's enrollment target sits among peer trials
80 49th of 99 higher than 51 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
RECRUITING · Early Phase 1
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
Customized TULSA-PRO Ablation Registry
RECRUITING
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI